Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
[1] A second large randomized trial of similar design (404 patients, with a 6-month efficacy phase and a 6-month extension) reproduced the effect, and patients who continued tesamorelin to 12 months showed a sustained VAT reduction of roughly 18%
A: In Phase 3 clinical trials, participants lost an average of approximately 7.9% to 8.7% of their total body weight over 36 to 40 weeks
doi: 10.1093/cercor/bht118 82
The peptide itself is prepared by a licensed compounding pharmacy, since the original FDA-approved drug is no longer manufactured or sold
Possible side effects include injection-site reactions, lightheadedness, and rare allergic reactions
Early symptoms: nausea, fatigue, loss of appetite, excessive thirst, frequent urination
